CE Stock Analysis: Celanese | NYSE
Chemicals | NYSE, USA | Market Cap: 4.731m USD | 12M Return: -9.6% | US1508701034 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 87.9M
EPS Trend: -86.6%
Qual. Beats: 1
Rev. Trend: -96.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Celanese Corporation is a global producer and seller of engineered polymers, operating through two segments: Engineered Materials and Acetyl Chain. The Engineered Materials segment supplies high-performance polymers and thermoplastics (such as polyoxymethylene, nylon compounds, liquid crystal polymers, and thermoplastic elastomers) used across automotive, consumer electronics, medical, construction, energy storage, and industrial applications. The Acetyl Chain segment provides acetyl-based products-including acetic acid, vinyl acetate monomers, acetate tows, and emulsions-that serve as building blocks for adhesives, coatings, flexible packaging, paints, textiles, and pharmaceutical applications. The company sells under a broad portfolio of brands (including Hostaform, Celanex, Santoprene, Hytrel, and Zytel) via direct sales, distributors, and OEMs, and was founded in 1912 with headquarters in Irving, Texas.
As a specialty chemicals company within the Materials sector, Celanese occupies a vertically integrated position in the acetyl value chain, converting basic feedstocks like ethylene and methanol into higher-margin intermediates and downstream polymers. Its dual-segment model pairs commodity-scale acetyl production with differentiated engineered materials, allowing the business to serve both volume-driven industrial customers and performance-driven specialty end markets.
- Acetyl chain margins pressured by weak acetic acid pricing
- Engineered Materials demand softens on automotive destocking
- Deleveraging from M&M acquisition remains key investor focus
| Net Income: -1.17b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.09 > 1.0 |
| NWC/Revenue: 11.11% < 20% (prev 29.26%; Δ -18.15% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.15b > Net Income -1.17b |
| Net Debt (11.3b) to EBITDA (175.0m): 64.63 < 3 |
| Current Ratio: 1.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (110.2m) vs 12m ago 0.42% < -2% |
| Gross Margin: 20.23% > 18% (prev 21.85%; Δ -1.62% > 0.5%) |
| Asset Turnover: 43.05% > 50% (prev 41.91%; Δ 1.13% > 0%) |
| Interest Coverage Ratio: -0.60 > 6 (EBIT TTM -457.0m / Interest Expense TTM 760.0m) |
| A: 0.05 (Total Current Assets 5.79b - Total Current Liabilities 4.72b) / Total Assets 21.4b |
| B: 0.47 (Retained Earnings 10.0b / Total Assets 21.4b) |
| C: -0.02 (EBIT TTM -457.0m / Avg Total Assets 22.6b) |
| D: 0.25 (Book Value of Equity 4.17b / Total Liabilities 16.8b) |
| Altman-Z'' = 1.98 = BBB |
| DSRI: 1.00 (Receivables 1.87b/1.92b, Revenue 9.71b/9.94b) |
| GMI: 1.08 (GM 21.85% / 20.23%) |
| AQI: 0.93 (AQ_t 0.49 / AQ_t-1 0.52) |
| SGI: 0.98 (Revenue 9.71b / 9.94b) |
| TATA: -0.11 (NI -1.17b - CFO 1.15b) / TA 21.4b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of August 09, 2026, the stock is trading at USD 43.89 with a total of 1,084,690 shares traded. Over the past week, the price has changed by -1.86%, over one month by -9.78%, over three months by -24.80% and over the past year by -9.57%.
Current recommended Stop Loss: 41.10 (which is 6.4% or 1.3 ATR below the current price).
Celanese has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy CE.
- StrongBuy: 8
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 67.5 | 53.8% |
P/E Forward = 7.4627
P/S = 0.4871
P/B = 1.2211
P/EG = 1.7421
Revenue TTM = 9.71b USD
EBIT TTM = -457.0m USD
EBITDA TTM = 175.0m USD
Long Term Debt = 11.4b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.31b USD (from shortTermDebt, last quarter)
Debt = 12.7b USD (from shortLongTermDebtTotal, last quarter) + Leases 351.0m
Net Debt = 11.3b USD (calculated: Debt 12.7b - CCE 1.36b)
Enterprise Value = 16.0b USD (4.73b + Debt 12.7b - CCE 1.36b)
Interest Coverage Ratio = -0.60 (Ebit TTM -457.0m / Interest Expense TTM 760.0m)
EV/FCF = 19.98x (Enterprise Value 16.0b / FCF TTM 803.0m)
FCF Yield = 5.01% (FCF TTM 803.0m / Enterprise Value 16.0b)
FCF Margin = 8.27% (FCF TTM 803.0m / Revenue TTM 9.71b)
Net Margin = -12.04% (Net Income TTM -1.17b / Revenue TTM 9.71b)
Gross Margin = 20.23% ((Revenue TTM 9.71b - Cost of Revenue TTM 7.75b) / Revenue TTM)
Gross Margin QoQ = 22.46% (prev 18.96%)
Tobins Q-Ratio = 0.75 (Enterprise Value 16.0b / Total Assets 21.4b)
Interest Expense / Debt = 6.00% (Interest Expense 760.0m / Debt 12.7b)
Taxrate = 7.75% (11.0m / 142.0m)
NOPAT = -421.6m (EBIT -457.0m * (1 - 7.75%)) [loss with tax shield]
Current Ratio = 1.23 (Total Current Assets 5.79b / Total Current Liabilities 4.72b)
Debt / Equity = 3.04 (Debt 12.7b / totalStockholderEquity, last quarter 4.17b)
Debt / EBITDA = 64.63 (Net Debt 11.3b / EBITDA 175.0m)
Debt / FCF = 14.09 (Net Debt 11.3b / FCF TTM 803.0m)
Total Stockholder Equity = 4.06b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.18% (Net Income -1.17b / Total Assets 21.4b)
RoE = -28.81% (Net Income TTM -1.17b / Total Stockholder Equity 4.06b)
RoCE = -2.96% (EBIT -457.0m / Capital Employed (Equity 4.06b + L.T.Debt 11.4b))
RoIC = -2.41% (negative operating profit) (NOPAT -421.6m / Invested Capital 17.5b)
WACC = 6.54% (E(4.73b)/V(17.4b) * Re(9.24%) + D(12.7b)/V(17.4b) * Rd(6.00%) * (1-Tc(0.08)))
Discount Rate = 9.24% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 81.17 | Cagr: 0.28%
[DCF] Terminal Value 77.97% ; FCFF base≈734.6m ; Y1≈842.1m ; Y5≈1.24b
[DCF] Fair Price = 66.92 (EV 18.7b - Net Debt 11.3b = Equity 7.34b / Shares 109.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -86.65 | EPS CAGR: -26.11% | SUE: 0.96 | # QB: 1
Revenue Correlation: -96.11 | Revenue CAGR: -5.12% | SUE: -0.34 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.77 | Chg30d=-4.20% | Revisions=-55% | Analysts=15
EPS current Year (2026-12-31): EPS=6.05 | Chg30d=-1.47% | Revisions=-10% | GrowthEPS=+51.9% | GrowthRev=+5.1%
EPS next Year (2027-12-31): EPS=6.42 | Chg30d=-3.09% | Revisions=-55% | GrowthEPS=+6.2% | GrowthRev=+0.7%
[Analyst] Revisions Ratio: -50% (up=5, down=18)